NCT04852328View on ClinicalTrials.gov

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

CUE-101

CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Cue Biopharma
All Listed Sponsors
collaborator

Cue Biopharma

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04852328 - Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | Biotech Hunter | Biotech Hunter